| CTA101 / Nanjing Bioheng Biotech |
| Unknown status | 1 | 15 | RoW | CTA101 | Kai Lin Xu; Jun Nian Zheng, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia | 11/21 | 06/22 | | |
NCT04227015: A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy |
|
|
| Recruiting | 1 | 72 | RoW | CTA101, CTA101 UCAR-T cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | 01/22 | 05/27 | | |
NCT04026100: CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 1 | 9 | RoW | CTA101 | The First Affiliated Hospital with Nanjing Medical University, Nanjing Bioheng Biotech Co., Ltd. | Diffuse Large B-cell Lymphoma | 08/22 | 12/22 | | |
ChiCTR2000039646: CTA101 cell injection in the treatment of patients with recurrent or refractory B-type hematologic malignancies |
|
|
| Recruiting | 1 | 30 | | The infusion of 0.5×10^6 CART+ cell/kg ;The infusion of 1.0×10^6 CART+ cell/kg ;The infusion of 1.0×10^6 CART+ cell/kg ;The infusion of 3.0×10^6 CART+ cell/kg ;The infusion of 6.0×10^6 CART+ cell/kg | Jiangsu Province Hospital; Jiangsu Province Hospital, Supported by Nanjing Bioheng Biotech Co.,Ltd | CD19阳性/CD22阳性复发或难治性B系恶性血液肿瘤 | | | | |
